Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

About this update from Autonomix Medical, Inc.

THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor ("Investor") for the immediate exercise of certain outstanding warrants that the Company issued on November 19, 2025 (the "November 2025 Warrants"). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding November 2025 Warrants to purchase an aggregate of 428,731 shares of the Company's common stock at the amended and reduced exercise price of $6.00. The resale of the shares of common stock issuable upon exercise of the November 2025 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333- 291825). The gross proceeds from the exercise of the warrants are expected to be approximately $2.6 million, prior to deducting financial advisory fees and estimated offering expenses. Maxim Group LLC acted as warrant inducement agent and financial advisor in connection with the transaction. In consideration for the immediate exercise of the existing warrants in cash, the Company also agreed to issue to the Investor unregistered Series D-1 warrants to purchase an aggregate of 428,731 shares of the Company's common stock, and Series D-2 warrants to purchase an aggregate of 428,731 shares of the Company's common stock (collectively, the "New Warrants"). The New Warrants will each have an exercise price of $5.75 per share, will be exercisable immediately upon issuance, and will expire on the five and one-half year anniversary of the date of issuance. The Company has agreed to file a registration statement with the Securities and Exchange Commission ("SEC") covering the resale of the shares of common stock issuable upon exercise of the New Warrants. The closing of the warrant exercise transaction is expected to occur on or about July 15, 2026, subject to satisfaction of customary closing conditions. The New Warrants described above are being offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "1933 Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under...

View stock analysis, news, and events for Autonomix Medical, Inc.